AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

Written by Petra Hegmann on 27th July 2021. Posted in Client News.

• Previous
• Next